Effect of haridradi tail in diabetic complication

Evaluation of clinical efficacy of Haridradi Tail snehpana in Apathyanimittaj prameha upadrava with special reference to endothelial inflammation in type II Diabetes Mellitus - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057793

Enrollment

200

Registered

2023-09-18

Start date

Unknown

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Subjects having signs and symptoms of prameha explained in Ayurvedic tests. Known patients of Type-II diabetes mellitus patients preliminarily diagnosed Type-II diabetes mellitus on the basis of signs and symptoms of disease will be confirmed by HbA1C, FBSL and PPBSL.

Exclusion criteria

Exclusion criteria: Type-II DM with PTCA or CABG history. Patient of Sahaja Prameha and having bala and dhatukshaya and Type – I Diabetes Mellitus. Patient undergoing regular treatment for any other severe illness patient suffering from tuberculosis, carcinoma, HIV positive patients endocrine disorders like thyrotoxicosis, cushing syndrome, conn syndrome,hypothyroidism with Type II DM. Patients suffering from malignant and accelerated hypertension, CVS disorders, pregnant women and planning to be pregnant within six months lactating mother secondary diabetes mellitus, diabetes ketoacidosis, CNS disorder e.g. encephalopathy, seizures. Auto-immune diseases. MODY (Maturity Onset of Diabetes in Youngs) Severe renal and hepatic failure. Secondary diabetes mellitus. History of acute and chronic pancreatitis. Acute Type II DM complication like HHNK & hypoglycemia. Diabetic under stress like infection, undergoing surgery, STEMI, NSTEMI, stroke, Trauma, repeated hypoglycemia, diabetic wounds

Design outcomes

Primary

Measure	Time frame
Improvement in sings and symptoms of diabetese mellitus Lowering of High-sensitivity C-reactive protein levelsTimepoint: 90 days	—

Secondary

Measure	Time frame
Relief in inflamatory conditionTimepoint: 90 days	—

Countries

India

Contacts

Public ContactDr Sanjeevani Rathod

Ayurved Seva Sangh Ayurved Mahavidyalaya Nashik

vaidyarajankulkarni@gmail.com9823350440

Outcome results